DADS联合P-gp抑制剂比立考达协同逆转A549/DDP多药耐药性的研究

摘要

目的：为研究DADS（二烯丙基二硫）联合第二代P-gp抑制剂比立考是否可协同逆转肺癌耐顺铂细胞株A549/DDP的多药耐药，增强化疗敏感性。方法 MTT进行药物毒性试验，Western和RT-PCR检测P-gp及其编码基因MDR-1表达变化。结果非细胞毒性剂量的8 mg/L DADS和2.3μmol/L的比立考达都可以增加CDDP（顺铂）对A549/DDP细胞毒性，且二者联合具有协同作用。并通过Western和PCR验证经8 mg/L DADS作用后耐药细胞系A549/DDP后P-gp与MDR-1表达明显降低，经8 mg/L DADS和2.3μmol/L的比立考达共同作用后A549/DDP后P-gp与MDR-1表达进一步降低。结论 DADS与比立考达在逆转肺癌多药耐药具有协同作用。%Objective To investigate the multidrug resistance synergistic reversing and the chemotherapy sensitivity enhancement buy DADS(diallyl trisulfide) and Biricodar on the multidrug resistancet of human lung A549/DDP cells.Methods MTT test drug sensitivity, the changes expression of MDR-1 and P-gp was examined by RT-PCR and Western blot.Results Using either non-cytotoxic dose 8 mg/L or 2.3 μmol/L Biricodar can make A549/DDP more sensitive to cisplatin, meanwhile, using DADS alone can decrease the level of MDR-1 and P-gp on A549/DDP cells, more over, the combination using DADS and Biricodar have more significant effect.Conclusion DADS and Biricodar have coordinate effect on reversing the multidrug resistance of human lung A549/DDP cells.